ASX · M7T.AX
Mach7 Technologies Limited
A$0.26+A$0.01 (+2.0%)
Mach7 Technologies Limited’s quoted price sits in the lower half of its reported 52-week range, 62.77% below the high.
Loading market information…
ASX · IPD.AX · AUD
Stock price, earnings
Quote as of Oct 30, 2026, 03:17 AM UTC. Cached market data; not a live quote.
One-year closing-price history · AUD. Historical prices are not a forecast.
ImpediMed Limited’s quoted price sits in the lower half of its reported 52-week range, 90.48% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
ImpediMed Limited’s next earnings report is currently expected on Feb 25, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow ImpediMed Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Operating as a medical software technology provider, ImpediMed Limited is responsible for the development, production, and global sales of bioimpedance spectroscopy (BIS) instruments and accompanying software solutions, serving markets in Australia, North America, and internationally. Its product portfolio features SOZO, a non-invasive BIS device used for evaluating lymphedema and tracking fluid levels in heart failure patients. Additionally, it offers the SFB7, a single-channel, tetrapolar BIS instrument for analyzing body composition in healthy individuals, and ImpediVET, another single-channel, tetrapolar BIS device specifically designed for veterinary applications to measure fluid status and tissue composition. ImpediMed primarily sells its technology to hospitals and clinics. This Australian-headquartered firm, based in Pinkenba, was established in 1999.
Latest available per-share figures in AUD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:41 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| -A$0.01+16.67% vs estimate |
| A$6.35M+15.45% vs estimate |
| Q2 2024 | Feb 26, 2024 | -A$0.010.0% vs estimate | A$4.80M-74.33% vs estimate |
|---|
| Q4 2023 | Aug 31, 2023 | -A$0.01 | A$5.60M-70.05% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
A$0.26+A$0.01 (+2.0%)
Mach7 Technologies Limited’s quoted price sits in the lower half of its reported 52-week range, 62.77% below the high.
A$0.18+A$0.00 (0.0%)
Singular Health Group Ltd’s quoted price sits in the lower half of its reported 52-week range, 40.0% below the high.
A$0.44+A$0.05 (+12.99%)
Cyclopharm Limited’s quoted price sits in the lower half of its reported 52-week range, 66.28% below the high.
A$0.23-A$0.01 (-2.13%)
Compumedics Limited’s quoted price sits in the lower half of its reported 52-week range, 48.89% below the high.
A$0.09-A$0.00 (-1.12%)
Amplia Therapeutics Limited’s quoted price sits in the lower half of its reported 52-week range, 68.0% below the high.
A$0.15A$0.00 (0.0%)
Nova Eye Medical Limited’s quoted price sits in the lower half of its reported 52-week range, 26.83% below the high.
A$0.37A$0.00 (0.0%)
Medical Developments International Limited’s quoted price sits in the lower half of its reported 52-week range, 48.61% below the high.
A$0.04-A$0.00 (-5.13%)
Micro-X Limited’s quoted price sits in the lower half of its reported 52-week range, 67.83% below the high.
